T2 Biosystems, Inc. (TTOO)

NASDAQ: TTOO · IEX Real-Time Price · USD
0.0998
+0.0019 (1.94%)
At close: Sep 27, 2022 4:00 PM
0.0990
-0.0008 (-0.80%)
After-hours: Sep 27, 2022 4:49 PM EDT
1.94%
Market Cap 35.18M
Revenue (ttm) 27.55M
Net Income (ttm) -60.64M
Shares Out 352.54M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,875,865
Open 0.0954
Previous Close 0.0979
Day's Range 0.0954 - 0.1037
52-Week Range 0.0890 - 1.0800
Beta 0.48
Analysts Buy
Price Target 0.20 (+100.4%)
Earnings Date Nov 2, 2022

About TTOO

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream i... [Read more...]

Industry Biotechnology
IPO Date Aug 7, 2014
CEO John Sperzel
Employees 182
Stock Exchange NASDAQ
Ticker Symbol TTOO
Full Company Profile

Financial Performance

In 2021, T2 Biosystems's revenue was $28.06 million, an increase of 54.76% compared to the previous year's $18.13 million. Losses were -$49.24 million, 5.22% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TTOO stock is "Buy." The 12-month stock price forecast is 0.2, which is an increase of 100.40% from the latest price.

Price Target
$0.2
(100.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What Is Going on With T2 Biosystems (TTOO) Stock Today?

T2 Biosystems (NASDAQ: TTOO ) stock got a 23% boost overnight after it announced a distribution agreement covering the Baltics. T2 makes test kits for detecting sepsis.

4 days ago - InvestorPlace

T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region

LEXINGTON, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the ex...

5 days ago - GlobeNewsWire

T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference

LEXINGTON, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans...

2 weeks ago - GlobeNewsWire

T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

LEXINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans ...

1 month ago - GlobeNewsWire

T2 Biosystems Announces Second Quarter 2022 Financial Results

T2Dx Instrument contracts increased by 300% compared to the prior year period T2Dx Instrument contracts increased by 300% compared to the prior year period

1 month ago - GlobeNewsWire

T2 Biosystems (TTOO) Stock Gains on Monkeypox Test News

Source: Viacheslav Lopatin / Shutterstock.com T2 Biosystems (NASDAQ: TTOO ) stock is getting a boost on Wednesday after announcing plans to investigate monkeypox tests. According to a press release from...

1 month ago - InvestorPlace

T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans t...

1 month ago - GlobeNewsWire

T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to tw...

1 month ago - GlobeNewsWire

T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022

LEXINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that i...

1 month ago - GlobeNewsWire

T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference

LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans ...

2 months ago - GlobeNewsWire

T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel

Molecular Diagnostic Test for Early Detection of Lyme Disease Molecular Diagnostic Test for Early Detection of Lyme Disease

2 months ago - GlobeNewsWire

T2 Biosystems Shares Slide As Interim Q2 Sales Trail Consensus

T2 Biosystems Inc (NASDAQ: TTOO) expects Q2 FY22 revenues of $5.8 million - $6.1 million, below the consensus of $6.87 million. The interim numbers include product revenue of $2.5 million - $2.7 million...

2 months ago - Benzinga

T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results

Implemented expense reductions including headcount during the second quarter Implemented expense reductions including headcount during the second quarter

2 months ago - GlobeNewsWire

T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022

LEXINGTON, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans ...

3 months ago - GlobeNewsWire

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that t...

3 months ago - GlobeNewsWire

T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease

LEXINGTON, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S....

4 months ago - GlobeNewsWire

T2 Biosystems Announces First Quarter 2022 Financial Results

Results driven by strong sepsis-focused instrument placements in the United States Results driven by strong sepsis-focused instrument placements in the United States

4 months ago - GlobeNewsWire

T2 Biosystems Announces Receipt of Nasdaq Delisting Notice

Company has Filed an Appeal and will Present a Plan to Regain Compliance Company has Filed an Appeal and will Present a Plan to Regain Compliance

4 months ago - GlobeNewsWire

T2 Biosystems Announces Formation and Members of Scientific Advisory Board

LEXINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the f...

4 months ago - GlobeNewsWire

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel

LEXINGTON, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that ...

5 months ago - GlobeNewsWire

T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022

LEXINGTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that ...

5 months ago - GlobeNewsWire

T2 Biosystems Reports Granting of Inducement Award

LEXINGTON, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to tw...

5 months ago - GlobeNewsWire

T2 Biosystems Secures Additional BARDA Funding To Develop Blood Test Panels To Detect Sepsis-Causing Pathogens

The Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems Inc (NASDA...

5 months ago - Benzinga

T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million

Advances U.S. Clinical Trials for T2Biothreat and T2Resistance and Continued Development of Next-Generation Diagnostics for the Detection of Bloodstream Infections and Antimicrobial Resistance Advances ...

5 months ago - GlobeNewsWire

T2 Biosystems to Host Analyst and Investor Day on April 12, 2022

LEXINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that ...

5 months ago - GlobeNewsWire